Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
NCT05498181Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacubitril + valsartan in end stage renal disease (ESRD), sponsored by Brigham and Women's Hospital. Started Oct 2022; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT05498181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498181.